MX2022015250A - Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. - Google Patents
Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.Info
- Publication number
- MX2022015250A MX2022015250A MX2022015250A MX2022015250A MX2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inflammatory diseases
- treating inflammatory
- diseases
- crohn
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se refiere generalmente a métodos para el tratamiento de enfermedades relacionadas con IL-23, en particular, enfermedades inflamatorias, tales como la enfermedad de Crohn, que utilizan anticuerpos anti-IL-23ª.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220410P | 2015-09-18 | 2015-09-18 | |
US201562235654P | 2015-10-01 | 2015-10-01 | |
US201662295643P | 2016-02-16 | 2016-02-16 | |
US201662328863P | 2016-04-28 | 2016-04-28 | |
US201662335242P | 2016-05-12 | 2016-05-12 | |
US201662339192P | 2016-05-20 | 2016-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015250A true MX2022015250A (es) | 2023-01-11 |
Family
ID=57003593
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003174A MX2018003174A (es) | 2015-09-18 | 2016-09-15 | Metodos para tratar enfermedades inflamatorias. |
MX2022015248A MX2022015248A (es) | 2015-09-18 | 2018-03-14 | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. |
MX2022015250A MX2022015250A (es) | 2015-09-18 | 2018-03-14 | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003174A MX2018003174A (es) | 2015-09-18 | 2016-09-15 | Metodos para tratar enfermedades inflamatorias. |
MX2022015248A MX2022015248A (es) | 2015-09-18 | 2018-03-14 | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170081402A1 (es) |
EP (1) | EP3350221A1 (es) |
JP (5) | JP6668461B2 (es) |
KR (1) | KR20180053395A (es) |
CN (1) | CN108026168A (es) |
AU (2) | AU2016323152A1 (es) |
BR (1) | BR112018003526A2 (es) |
CA (1) | CA2996645A1 (es) |
CL (1) | CL2018000597A1 (es) |
EA (1) | EA201890747A1 (es) |
HK (1) | HK1252037A1 (es) |
IL (2) | IL302197A (es) |
MX (3) | MX2018003174A (es) |
PH (1) | PH12018500578A1 (es) |
TW (2) | TWI733695B (es) |
WO (1) | WO2017048901A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103282382B (zh) | 2010-11-04 | 2017-11-03 | 勃林格殷格翰国际有限公司 | 抗il‑23抗体 |
KR102124758B1 (ko) | 2012-05-03 | 2020-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23p19 항체 |
JP2017524359A (ja) | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−23a関連疾患の処置に有用なバイオマーカー |
TWI733695B (zh) * | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
EP3677597A1 (en) * | 2016-10-14 | 2020-07-08 | Boehringer Ingelheim International GmbH | Methods of treating diseases |
JP2021515770A (ja) * | 2018-03-05 | 2021-06-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗il−23特異的抗体を用いたクローン病の治療方法 |
TW202103734A (zh) | 2019-04-22 | 2021-02-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
CN112578123B (zh) * | 2019-09-27 | 2022-10-25 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途 |
MX2023007933A (es) | 2021-01-06 | 2023-09-15 | Abbvie Inc | Métodos para tratar la enfermedad de crohn y la colitis ulcerosa. |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
EP1896073B1 (en) * | 2005-06-30 | 2013-03-06 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
MX2008002179A (es) * | 2005-08-25 | 2008-04-22 | Lilly Co Eli | Anticuerpos anti-il-23. |
ES2619845T3 (es) | 2005-08-31 | 2017-06-27 | Merck Sharp & Dohme Corp. | Anticuerpos anti-IL-23 diseñados por ingeniería genética |
ES2517420T3 (es) | 2005-12-29 | 2014-11-03 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos |
CN101600456A (zh) * | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
CN103396489A (zh) * | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
JO3244B1 (ar) * | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
CN103282382B (zh) * | 2010-11-04 | 2017-11-03 | 勃林格殷格翰国际有限公司 | 抗il‑23抗体 |
KR102124758B1 (ko) * | 2012-05-03 | 2020-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23p19 항체 |
CN105307675A (zh) * | 2013-03-15 | 2016-02-03 | 美国安进公司 | 使用抗il23抗体治疗克罗恩氏病的方法 |
TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
JP7060806B2 (ja) * | 2018-08-22 | 2022-04-27 | 富士通株式会社 | 情報処理装置、データ管理方法およびデータ管理プログラム |
JP2020030579A (ja) * | 2018-08-22 | 2020-02-27 | 信越ポリマー株式会社 | Rfidタグ埋設体およびその製造方法 |
-
2016
- 2016-09-14 TW TW105129972A patent/TWI733695B/zh active
- 2016-09-14 TW TW110123878A patent/TWI811716B/zh active
- 2016-09-15 KR KR1020187010883A patent/KR20180053395A/ko not_active Application Discontinuation
- 2016-09-15 US US15/266,170 patent/US20170081402A1/en active Pending
- 2016-09-15 JP JP2018513853A patent/JP6668461B2/ja active Active
- 2016-09-15 AU AU2016323152A patent/AU2016323152A1/en not_active Abandoned
- 2016-09-15 EP EP16771052.4A patent/EP3350221A1/en active Pending
- 2016-09-15 IL IL302197A patent/IL302197A/en unknown
- 2016-09-15 EA EA201890747A patent/EA201890747A1/ru unknown
- 2016-09-15 CN CN201680054412.0A patent/CN108026168A/zh active Pending
- 2016-09-15 WO PCT/US2016/051844 patent/WO2017048901A1/en active Application Filing
- 2016-09-15 MX MX2018003174A patent/MX2018003174A/es unknown
- 2016-09-15 BR BR112018003526A patent/BR112018003526A2/pt active Search and Examination
- 2016-09-15 CA CA2996645A patent/CA2996645A1/en active Pending
-
2018
- 2018-02-15 IL IL257561A patent/IL257561A/en unknown
- 2018-03-07 CL CL2018000597A patent/CL2018000597A1/es unknown
- 2018-03-14 MX MX2022015248A patent/MX2022015248A/es unknown
- 2018-03-14 MX MX2022015250A patent/MX2022015250A/es unknown
- 2018-03-16 PH PH12018500578A patent/PH12018500578A1/en unknown
- 2018-09-05 HK HK18111369.0A patent/HK1252037A1/zh unknown
-
2020
- 2020-02-26 JP JP2020030580A patent/JP7000476B2/ja active Active
- 2020-02-26 JP JP2020030579A patent/JP2020100643A/ja active Pending
-
2021
- 2021-12-23 JP JP2021209087A patent/JP7477492B2/ja active Active
-
2022
- 2022-03-23 JP JP2022046728A patent/JP2022088478A/ja active Pending
-
2023
- 2023-06-06 AU AU2023203530A patent/AU2023203530A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7477492B2 (ja) | 2024-05-01 |
JP6668461B2 (ja) | 2020-03-18 |
MX2018003174A (es) | 2018-05-17 |
JP2020100644A (ja) | 2020-07-02 |
EP3350221A1 (en) | 2018-07-25 |
US20170081402A1 (en) | 2017-03-23 |
CL2018000597A1 (es) | 2018-07-27 |
JP2020100643A (ja) | 2020-07-02 |
AU2023203530A1 (en) | 2023-07-06 |
TW201722474A (zh) | 2017-07-01 |
JP7000476B2 (ja) | 2022-02-04 |
TW202138008A (zh) | 2021-10-16 |
HK1252037A1 (zh) | 2019-05-10 |
IL257561A (en) | 2018-04-30 |
BR112018003526A2 (pt) | 2018-09-25 |
JP2022046624A (ja) | 2022-03-23 |
PH12018500578A1 (en) | 2018-09-10 |
TWI811716B (zh) | 2023-08-11 |
JP2018527380A (ja) | 2018-09-20 |
AU2016323152A1 (en) | 2018-02-22 |
EA201890747A1 (ru) | 2018-10-31 |
WO2017048901A1 (en) | 2017-03-23 |
KR20180053395A (ko) | 2018-05-21 |
IL302197A (en) | 2023-06-01 |
CN108026168A (zh) | 2018-05-11 |
JP2022088478A (ja) | 2022-06-14 |
CA2996645A1 (en) | 2017-03-23 |
MX2022015248A (es) | 2023-01-11 |
TWI733695B (zh) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
ZA201905488B (en) | Tigit- and light-based chimeric proteins | |
ZA201801852B (en) | Anti¿pd¿1 antibodies and compositions | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
GB2541571A (en) | Pharmaceutical compositions | |
MX2022006573A (es) | Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias. | |
EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
MX2021008663A (es) | Anticuerpos mejorados contra il-6. | |
WO2015187521A3 (en) | Anti-blys antibodies | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
WO2018071504A3 (en) | Methods of treating diseases with il-23a antibody | |
MX2017006692A (es) | Trastornos neurodegenerativos. | |
MX2019014291A (es) | Metodo de tratamiento. | |
PH12017501872A1 (en) | Methods of treating diseases | |
WO2017042577A8 (en) | Novel therapy | |
PH12018500339A1 (en) | Lysobactin for use in the treatment of bovine mastitis |